Nemera Wins ‘Best New Product’ at INTERPHEX
The company’s preservative-free multidose eyedropper wins award.
Nemera’s Novelia BFS, a preservative-free multi-dose eyedropper, received the ‘Best New Product’ INTERPHEX Exhibitor Award at INTERPHEX 2016. Novelia BFS was presented at the opening ceremony of INTERPHEX on April 26, 2016.
According to a company press release, Novelia is user-friendly, “works with high viscosity suspensions and solutions of up to 1500 cps, and limits the distribution of liquids to one drop at a time. The doses of the drops are precise, which assist medication adherence. Nemera and Rommelag combined their technologies and experiences to create a preservative-free multidose ophthalmic dropper processed by blow-fill-seal.”
The INTERPHEX Exhibitor Award evaluates submissions based on overall design, knowledge, innovation, new technology or novel implementation of existing technology, advances in features and performance, advances in services provision, significant new services additions, and showcasing of technical knowledge.
Source: Nemera
Drug Solutions Podcast: A Closer Look at mRNA in Oncology and Vaccines
April 30th 2024In this episode fo the Drug Solutions Podcast, etherna’s vice-president of Technology and Innovation, Stefaan De Koker, discusses the merits and challenges of using mRNA as the foundation for therapeutics in oncology as well as for vaccines.
Drug Solutions Podcast: Gliding Through the Ins and Outs of the Pharma Supply Chain
November 14th 2023In this episode of the Drug Solutions podcast, Jill Murphy, former editor, speaks with Bourji Mourad, partnership director at ThermoSafe, about the supply chain in the pharmaceutical industry, specifically related to packaging, pharma air freight, and the pressure on suppliers with post-COVID-19 changes on delivery.
Shilpa Medicare Launches ‘Hybrid CDMO’ at DCAT Week 2025
March 17th 2025This model is being positioned by Shilpa as a dual approach that offers comprehensive discovery, clinical, and commercial outsourcing services in addition to commercially ready, “off-the-shelf” novel formulations for b2b licensing.
